XNAS
HSDT
Market cap148mUSD
Oct 08, Last price
2.38USD
1D
-6.30%
1Q
36.00%
Jan 2017
-100.00%
IPO
-100.00%
Name
Helius Medical Technologies Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Helius Medical Technologies, Inc. operates as a neurotechnology firm, dedicated to conceiving, licensing, and incorporating non-invasive technologies. These innovations aim to alleviate symptoms stemming from neurological disorders or injuries. Its flagship product is the Portable Neuromodulation Stimulator (PoNS), a medical apparatus sanctioned for use in Canada to address chronic balance impairments associated with mild-to-moderate traumatic brain injury. The PoNS system functions by stimulating cranial nerves via the tongue, with the goal of rehabilitating compromised bodily functions. The company's main offices are located in Newtown, Pennsylvania.
Key people
Dane Andreeff
President, Chief Executive Officer, Director · since 2021
Chief Financial Officer, Treasurer, Secretary, Director · since 2022
Joseph Chee
Executive Chairman of the Board · since 2025
Antonella Favit-Van Pelt
Chief Medical Officer · since 2021
Cosmo Jiang
Director · since 2025
Paul Buckman
Independent Director · since 2021
Sherrie Perkins
Independent Director · since 2021
Edward Straw
Independent Director · since 2014
Blane Walter
Independent Chairman of the Board · since 2020
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||